Loading…
AC Immune SA is projected to rise to $2.46 by 2027, a +3% move from its current price of $2.39. ACIU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.31 | $2.39 | $2.48 | -0.01% |
| Jul 14 | $2.27 | $2.39 | $2.51 | -0.02% |
| Jul 15 | $2.25 | $2.39 | $2.54 | -0.03% |
| Jul 16 | $2.22 | $2.39 | $2.57 | -0.03% |
| Jul 17 | $2.20 | $2.39 | $2.59 | -0.04% |
| Jul 18 | $2.19 | $2.39 | $2.61 | -0.05% |
| Jul 19 | $2.17 | $2.39 | $2.63 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.17 | $2.39 | $2.63 | -0.06% |
| Week 2 | $2.09 | $2.39 | $2.73 | -0.12% |
| Week 3 | $2.02 | $2.39 | $2.81 | -0.18% |
| Week 4 | $1.97 | $2.38 | $2.88 | -0.24% |
| Week 5 | $1.93 | $2.38 | $2.95 | -0.30% |
| Week 6 | $1.89 | $2.38 | $3.01 | -0.36% |
| Week 7 | $1.85 | $2.38 | $3.06 | -0.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AC Immune SA is a clinical stage biopharmaceutical company that discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
The company develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. In addition, AC Immune is pursuing programs such as ACI-24.060 for Down syndrome related AD; ACI-7104.056 for Parkinson’s disease; and ACI-35.030 designed to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau. It also develops diagnostic programs including PI-2620, a Tau diagnostic for AD and non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer for differential diagnosis of multiple system atrophy.
Incorporated in 2003 and headquartered in Lausanne, Switzerland, the company also explores Morphomer Tau aggregation inhibitors and other discovery and preclinical stage molecules targeting a range of neurodegenerative diseases, including diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
AC Immune SA (ACIU) is a healthcare stock currently trading at $2.54 per share, with a market cap of $258.5M and a rank of 3623. The price outlook is captured in a year-by-year forecast spanning 2026 to 2050, showing a path from a current level toward higher average prices and ROIs in coming years. The forecast highlights a transition from a near-term baseline to stronger gains in the late-2020s and beyond, with bullish sentiment indicated for 2030, 2040, and 2050.
Current metrics anchor the narrative: the stock trades at $2.54 with a market cap of $258.5M and a rank of 3623. The 2026 forecast aligns with the current price, and subsequent years project a rising average price and substantial ROIs through 2050, signaling a long-run uptrend while acknowledging the uncertainty inherent in such projections.
A major floor 25.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.3% below — buyers have tended to step in here.
The nearest ceiling, 15.1% above — a clean break opens room to run.
A major ceiling 42.3% above — clearing it would confirm fresh momentum.
Key ACIU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACIU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.51 | Sell | $2.49 | Sell |
| MA 10 | $2.51 | Sell | $2.49 | Sell |
| MA 20 | $2.45 | Sell | $2.49 | Sell |
| MA 50 | $2.61 | Sell | $2.59 | Sell |
| MA 100 | $2.77 | Sell | $2.72 | Sell |
| MA 200 | $2.98 | Sell | $2.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.75 | Neutral |
| Stoch RSI (14) | 2.35 | Buy |
| CCI (20) | -45.55 | Neutral |
| Williams %R (14) | -96.43 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.45 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 3.57 | Buy |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 49.67 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 2.53 | Sell |
| ADX (14) | 12.26 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is neutral, with RSI(14) at 50. This suggests balanced momentum near the midpoint of the scale.
Over the short term, the asset trades relative to its moving averages, with a SMA50 of $2.72 and a SMA200 of $2.98. Immediate support is at $2.12 and resistance at $2.93, framing a near-term trading zone. The 30-day price range spans from $2.10 to $3.08, outlining the current volatility corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.12 | $2.39 | $2.83 | 0% | Neutral | |
| $1.90 | $2.46 | $3.39 | +3% | Neutral | |
| $1.73 | $2.32 | $3.36 | -3% | Neutral | |
| $1.74 | $2.42 | $3.63 | +1% | Neutral | |
| $1.97 | $2.81 | $4.35 | +18% | Neutral | |
| $2.15 | $3.16 | $5.02 | +32% | Bullish | |
| $2.56 | $3.84 | $6.24 | +61% | Bullish | |
| $2.57 | $3.95 | $6.57 | +65% | Bullish | |
| $2.27 | $3.57 | $6.04 | +49% | Bullish | |
| $2.42 | $3.89 | $6.71 | +63% | Bullish | |
| $3.41 | $6.04 | $11.22 | +153% | Bullish | |
| $4.27 | $9.02 | $18.64 | +277% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.12 | $2.39 | $2.82 | +0.00% |
| August 2026 | $1.95 | $2.32 | $2.85 | -2.93% |
| September 2026 | $1.97 | $2.37 | $2.96 | +2.21% |
| October 2026 | $1.92 | $2.32 | $2.93 | -1.99% |
| November 2026 | $1.81 | $2.20 | $2.81 | -5.17% |
| December 2026 | $1.79 | $2.20 | $2.83 | -0.08% |
Click any year to see its month-by-month ACIU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
AC Immune SA's 2026 outlook centres on $2.39, within a $2.12 to $2.83 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ACIU could reach as high as $3.39, with a base case around $2.46 and support toward $1.90 — roughly +3% from $2.39. Price action looks broadly range-bound.
Expect ACIU to range from $1.73 to $3.36 through 2028. The $2.32 average target implies a -3% move from current prices. That is -6% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The ACIU price prediction for 2029 points to an average of $2.42 (low $1.74, high $3.63) — a potential gain of +1% on today's $2.39. Price action looks broadly range-bound.
In 2030, ACIU is projected to trade between $1.97 and $4.35, averaging $2.81 — a potential gain of +18% from today's $2.39. That is up +16% on the projected 2029 average. A consolidation phase looks the most probable path here.
AC Immune SA's 2031 outlook centres on $3.16, within a $2.15 to $5.02 range. That is up +12% on the projected 2030 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2032, ACIU could reach as high as $6.24, with a base case around $3.84 and support toward $2.56 — roughly +61% from $2.39. Buyers look set to stay in control over this stretch.
Expect ACIU to range from $2.57 to $6.57 through 2033. The $3.95 average target implies a +65% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The ACIU price prediction for 2034 points to an average of $3.57 (low $2.27, high $6.04) — a potential gain of +49% on today's $2.39. Buyers look set to stay in control over this stretch.
In 2035, ACIU is projected to trade between $2.42 and $6.71, averaging $3.89 — a potential gain of +63% from today's $2.39. That is up +9% on the projected 2034 average. Momentum favours further upside here.
AC Immune SA's 2040 outlook centres on $6.04, within a $3.41 to $11.22 range. That is up +55% on the projected 2035 average. That marks a +153% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ACIU could reach as high as $18.64, with a base case around $9.02 and support toward $4.27 — roughly +277% from $2.39. Momentum favours further upside here.
Investing $1,000 in ACIU today (≈ 418.410042 ACIU) could be worth
$3,773.74
+$2,773.74 (+277%) by 2050 · US Dollar
Based on the average projected ACIU price of $9.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACIUwould be worth at today's price.
$1,000 invested in ACIU on Jul 10, 2025 (≈ 473.933673 ACIU) would be worth
$1,132.7
+$132.7 (+13.3%) today · 1.13× · US Dollar
Based on a ACIU entry price of $2.11 vs. today's $2.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.51 | $952.19 | -4.8% |
| 1 month ago | $2.12 | $1,127.36 | +12.7% |
| 3 months ago | $3.28 | $728.66 | -27.1% |
| 6 months ago | $3.52 | $678.98 | -32.1% |
| 1 year ago | $2.11 | $1,132.7 | +13.3% |
| All time (5.0y) ago | $7.88 | $303.3 | -69.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACIU forecast.
Our base-case forecast reaches $4.80 around 2040.
Implied market cap at $4.80: $488.51M
The multi-year forecast shows a bullish trajectory beyond 2026, with the 2030 average price projected at $3.09 and a max of $4.56, yielding an ROI of 21.8% in that year. The 2040 forecast strengthens to an average of $6.56 and a max of $11.31, with an ROI of 158.2%. By 2050, the average is $10.47 and the max $19.82, delivering an ROI of 312%.
The 2026 forecast places the average at $2.54 with a min of $2.12 and a max of $3.07, and an ROI of 0, anchoring the near term to the current price level. Across the horizon, the sentiment remains BULLISH for 2030, 2040, and 2050, reflecting an anticipated long-term appreciation despite the inherent uncertainty of equity forecasting. These figures are estimates and are not guaranteed.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.09, with a min of $2.27 and a max of $4.56, and an ROI of 21.8%. The sentiment is BULLISH.
Forecasts indicate a bullish trajectory from 2030 onward, with 2030 average at $3.09, 2040 average at $6.56, and 2050 average at $10.47, along with ROIs of 21.8%, 158.2%, and 312% respectively. These are estimates and carry inherent risk.
Yes. The 2040 forecast shows a maximum of $11.31, indicating the potential to exceed $11 in that year as per the projection.
The current price is $2.54 per share and the market cap is $258.5M.
RSI(14) is 50, SMA50 is $2.72, SMA200 is $2.98. Support is at $2.12 and resistance at $2.93, with a 30-day range from $2.10 to $3.08 and annualized volatility of 60%.
AC Immune SA Community Discussion
0Share your AC Immune SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.